Here are some great blog posts by Tim Street about his experiences and comments about the new faster-acting insulin, Fiasp.
- 48 hours with Fiasp. What are my first thoughts on Faster insulin Aspart?
- My month with the newest kid on the block & a hypothesis on the #Fiasp effects
And from ASweetLife.com: Just How Quick is Fiasp, Novo Nordisk’s Faster-Acting Insulin?
Roche helps Senseonics raise $41M to push diabetes device, as reported in FierceBiotech, 5/26/2017.
Senseonics is set to raise $41 million to support the anticipated commercialization of implantable continuous glucose monitoring (CGM) system Eversense. The fundraising attracted the support of major existing shareholders New Enterprise Associates (NEA) and Roche.
Senseonics’ is developing an implantable sensor. Once inserted by a doctor, the sensor uses fluorescence technology to measure glucose levels in the interstitial fluids. The sensor sends readings to a wearable patch that, in turn, processes the data and relays information to a smartphone app. Users are alerted when the technology forecasts glucose levels will exceed preset targets. The sensor lasts up to 90 days.
Read more: Roche helps Senseonics raise $41M to push diabetes device
Apple CEO Tim Cook Test-Drives a Blood Sugar Tracker, as reported by CNBC, 5/18/2017.
Tim Cook has been spotted at the Apple campus test-driving a device that tracks blood sugar, which was connected to his Apple Watch. A source said that Cook was wearing a prototype glucose-tracker on the Apple Watch, which points to future applications that would make the device a “must have” for millions of people with diabetes — or at risk for the disease.
Read more: Apple CEO Tim Cook test-drove a device that tracks his blood sugar
Nevada bill could force Sanofi, Novo and Lilly to reveal their insulin pricing secrets, as reported by FiercePharma, 5/22/2017.
As a variety of states weigh measures targeting pharmaceutical pricing, Nevada’s Senate has passed a tough new bill that would publicly spotlight insulin makers’ price hikes and profits.
Approved by the Nevada Senate on Friday, the bill would force diabetes drugmakers to disclose information on their insulin pricing, profits, costs and more, and would require the state government to publish the information publicly on the internet
Read more: Nevada bill could force Sanofi, Novo and Lilly to reveal their insulin pricing secrets
I do not see the proposed Nevada law holding up int eh supreme court if it is passed. When we look at the court in the recent past, it appears that business is given preference. I personally fear a Nevada like law, since a sweeping Supreme Court decision could ultimately tie the hands all states and the federal government to enact laws that do good things for insulin pricing. we shall see if it is approved.